Anika Therapeutics Inc
SWB:AKP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Anika Therapeutics Inc
SWB:AKP
|
US |
|
C
|
Campbell's Co
DUS:CSC
|
US |
|
A
|
Atlanta Braves Holdings Inc
NASDAQ:BATRA
|
US |
|
P
|
Pitney Bowes Inc
F:PBW
|
US |
|
Home First Finance Company India Ltd
BSE:543259
|
IN |
|
R
|
Regions Financial Corp
F:RN7
|
US |
|
America Movil SAB de CV
BMV:AMXB
|
MX |
|
A
|
Artisan Partners Asset Management Inc
F:AP0
|
US |
|
Eagle Materials Inc
F:E5M
|
US |
|
S
|
Sumitomo Mitsui Financial Group, Inc
SWB:XMF
|
JP |
|
A
|
Air Products and Chemicals Inc
F:AP3
|
US |
|
P
|
Pebblebrook Hotel Trust
SWB:PD0
|
US |
|
A
|
Air Products and Chemicals Inc
DUS:AP3
|
US |
|
I
|
IPD Group Ltd
ASX:IPG
|
AU |
Wall St Price Targets
AKP Price Targets Summary
Anika Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
AKP is 18.28 EUR with a low forecast of 18.1 EUR and a high forecast of 18.82 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AKP's stock price target?
Price Target
18.28
EUR
According to Wall Street analysts, the average 1-year price target for
AKP is 18.28 EUR with a low forecast of 18.1 EUR and a high forecast of 18.82 EUR.
What is the Revenue forecast for Anika Therapeutics Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 8%.
What is the Gross Profit forecast for Anika Therapeutics Inc?
Projected CAGR
14%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 2 years is 14%.